Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, Waldeström’s macroglobulinem...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-01-01
|
| Series: | Acta Haematologica Polonica |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/acta_haematologica_polonica/article/view/104338 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|